Nirsevimab is protective against RSV infections and coinfections, which suggests there is no replacement of RSV with other viruses post-nirsevimab administration.

US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...

RSV is a common virus that affects the lungs and breathing passages, and here are some steps you can take to protect yourself ...

From today, February 3, pregnant women in Australia will be eligible for a free RSV vaccine under the National Immunisation ...

COVID-19 was associated with more severe disease outcomes than influenza or RSV during the 2022 to 2023 season.

As health officials report a surge of winter viruses, health experts are warning that heart disease symptoms can sometimes ...

More than 86,000 recorded cases of respiratory syncytial virus in 2024 were in children younger than four years old.

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

Pregnant women in the Northern Territory (NT) can now receive the respiratory syncytial virus (RSV) vaccine for free under the National Immunisation ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary ... period with a higher AUC implying a more intense infection. The trial involved 114 healthy adults who ...

COVID-19 continues to be a threat to America’s health, causing more illness and death than either influenza or resp ...

Flu is a viral infection affecting the nose, throat and lungs, mostly during the winter months. It is far worse than an ...